

CLAIM AMENDMENT

Please amend the claims as set forth below:

1.-19. (Canceled)

20. (Currently amended) A method for decreasing drug resistance in a target ~~bacteria, yeast, plant or mammalian~~ cell comprising introducing to the cell a drug resistance-inhibiting amount of an ecto-phosphatase inhibitory molecule.

21.-24. (Canceled)

25. (Previously presented) The method of claim 20, further comprising down-regulating an ABC transporter in said cell.

26. (Currently Amended) The method of claim 20, wherein said ecto-phosphatase is selected from the group consisting of *Pisum sativum* apyrase and *Homo sapiens* apyrase.

27. (Currently Amended) The method of claim 25, wherein the ABC transporter is selected from the group consisting of *Arabidopsis thaliana* AtPGP-1, *Homo sapiens* Pgp, *Homo sapiens* MDR-3, *Saccharomyces cerevisiae* STS1, *Saccharomyces cerevisiae* Pdr5p, *Aspergillus fumigatus* Afu MDR1 and *Lactococcus lactis* LmrA.

28.-31. (Canceled)

32. (Previously presented) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula I.

33. (Previously presented) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula II.

34. (Previously presented) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula III.

35. (Previously presented) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula IV.

36. (Previously presented) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula V.

37. (Previously presented) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula VI.

38. (Previously presented) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula VII.

39. (Previously presented) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula VIII.

40. (Previously presented) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula IX.

41. (Previously presented) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula X.

42. (Previously presented) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XI.

43. (Previously presented) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XII.

44. (Previously presented) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XIII.

45. (Previously presented) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XIV.

46. (Previously presented) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XV.

47. (Previously presented) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XVI.


48. (Previously presented) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XVII.

49. (Previously presented) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XVIII.


50. (Previously presented) The method of claim 51, wherein the ecto-phosphatase inhibitory molecule is a molecule having Formula XIX.

51. (Previously presented) The method of claim 20, wherein the ecto-phosphatase inhibitory molecule is selected from the group consisting of molecules having the Formulae I through XIX:


I




II




III




IV




V




VI




VII




VIII




IX




X




XI




XII




XIII




XIV




XV




XVI




XVII



XVIII



XIX



RESPONSE TO THIRD OFFICE ACTION

A. Status of the Application

Applicants traversal of the earlier Restriction Requirement was found non-persuasive and the restriction made final in the Office Action. It was thus stated in the Action that claims 25, 27 and 33-50 were withdrawn from consideration. However, the Restriction Requirement was made in contravention of the relevant rules and thus Applicants are concurrently filing a Petition Under 37 C.F.R. §1.144 requesting revocation of the Restriction Requirement.

The current paper is fully responsive to the Action. The amendments made do not add subject matter outside the scope of the claims presented prior to the Action. Therefore, should any future rejections be made to claims not considered in this Action due to the Restriction Requirement, Applicants respectfully request that the Action be made non-final.

B. Status of the Claims

Claims 20-21 and 25-51 were pending at the time of the Action. Claims 21 and 28-31 have been canceled herein in light of the species election. Claims 20, 25-27 and 32-51 are now pending and presented for reconsideration.

C. Status of the Specification

Applicants note that the specification has been amended herein as requested at page 31 to delete reference to an embedded hyperlink. The objection is therefore now moot.